Highlights
1 patent
About
Peptide Development and Manufacture
Novetide manufactures commercially available peptide products, with a robust pipeline of products in development. The companys technology platform is based on several proprietary technologies and expertise in the development and production of peptides through sequence assembly, downstream processing, characterization, and documentation of peptide drug substances. Novetides two FDA-approved production sites have flexible and scalable manufacturing capabilities, with output ranging from grams to tons. Its peptides are currently sold to multinational pharmaceutical companies, start-up companies, and researchers worldwide. Teva Pharmaceuticals has held 50% of Novetide since 2000.
Identity
| Name | Novetide |
|---|---|
| Slug | novetide |
| Type / kind | startup |
| Crunchbase ID | novetide |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6u25gJDA |
Status
| Status | inactive |
|---|---|
| Status reason | Acquired (Inactive) by Undisclosed Investor(s) on Mar 2022 - ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | North District |
| HQ city | Kiryat Ata |
| HQ address | Derech Deshanim 1, Kiryat Ata, Israel |
Web & social
| https://www.linkedin.com/company/1228122 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
biopharmaceuticalbiotechnologymanufacturingpharma-companiespeptidespharmaceuticals
Funding
| Total raised | — |
|---|---|
| Current stage | Acquired |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}